• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526

Recent Advances in the Study of 4-(2-Chlorophenylthio)Benzoic Acid (CAS: 141358-09-0): A Comprehensive Research Brief

4-(2-Chlorophenylthio)Benzoic Acid (CAS: 141358-09-0) is a chemically synthesized compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This research brief aims to provide an up-to-date overview of the latest studies involving this compound, focusing on its synthesis, biological activities, and potential clinical applications. The compound's unique structure, featuring a chlorophenylthio moiety attached to a benzoic acid backbone, makes it a promising candidate for drug development, particularly in the areas of anti-inflammatory and anticancer therapies.

Recent studies have explored the molecular mechanisms underlying the biological effects of 4-(2-Chlorophenylthio)Benzoic Acid. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent inhibitory activity against cyclooxygenase-2 (COX-2), an enzyme implicated in inflammatory processes. The researchers utilized X-ray crystallography to elucidate the binding mode of the compound within the COX-2 active site, revealing key interactions that contribute to its selectivity and potency. These findings suggest that 4-(2-Chlorophenylthio)Benzoic Acid could serve as a lead compound for the development of novel anti-inflammatory drugs with improved safety profiles compared to traditional NSAIDs.

In the realm of oncology research, a 2024 preclinical study published in Cancer Research investigated the anticancer properties of 4-(2-Chlorophenylthio)Benzoic Acid. The compound was shown to induce apoptosis in various cancer cell lines, including breast and colon cancer, through modulation of the PI3K/AKT/mTOR signaling pathway. Importantly, the study reported synergistic effects when the compound was combined with conventional chemotherapeutic agents, potentially offering a strategy to overcome drug resistance. These results highlight the compound's potential as an adjunct therapy in cancer treatment regimens.

The pharmacokinetic profile of 4-(2-Chlorophenylthio)Benzoic Acid has also been a subject of recent investigation. A 2023 study in Drug Metabolism and Disposition characterized the compound's absorption, distribution, metabolism, and excretion (ADME) properties in animal models. The researchers found that the compound exhibits favorable oral bioavailability and a reasonable half-life, though they noted that further optimization may be required to improve its metabolic stability. These findings provide valuable insights for future formulation development and dosing strategies.

From a synthetic chemistry perspective, recent advances have been made in optimizing the production of 4-(2-Chlorophenylthio)Benzoic Acid. A 2024 publication in Organic Process Research & Development described a novel, scalable synthesis route that improves yield and reduces environmental impact compared to traditional methods. The new approach employs greener solvents and catalytic systems, aligning with the pharmaceutical industry's increasing focus on sustainable manufacturing practices.

Looking forward, several research groups have initiated structure-activity relationship (SAR) studies to develop analogs of 4-(2-Chlorophenylthio)Benzoic Acid with enhanced pharmacological properties. Preliminary results from these investigations, presented at recent conferences, suggest that modifications to the chlorophenyl ring or the benzoic acid moiety can significantly alter the compound's biological activity and selectivity. These efforts may lead to the discovery of second-generation compounds with improved therapeutic indices.

In conclusion, the growing body of research on 4-(2-Chlorophenylthio)Benzoic Acid (CAS: 141358-09-0) demonstrates its considerable potential as a therapeutic agent. While challenges remain in terms of further optimization and clinical translation, the compound's diverse biological activities and relatively favorable pharmacokinetic profile make it a promising candidate for continued investigation. Future research directions likely will focus on elucidating its precise molecular targets, exploring combination therapies, and advancing the most promising derivatives through preclinical development.

• 105917-74-6(Benzoic acid, 2,3-dichloro-4-(methylthio)-)
• 62268-13-7(1,2-Benzenedicarboxylic acid, 4-chloro-5-(methylthio)-)
• 141358-06-7(Benzoic acid, 3-[(3-chlorophenyl)thio]-)
• 413582-76-0(4-{(2,5-dichlorophenyl)sulfanylmethyl}benzoic acid)
• 847783-87-3(3-{(2,5-dichlorophenyl)sulfanylmethyl}benzoic acid)
• 62176-41-4( )
• 141358-10-3(Benzoic acid, 4-[(3-chlorophenyl)thio]-)
• 141358-07-8(Benzoic acid, 3-[(4-chlorophenyl)thio]-)
• 141358-05-6(3-(2-Chlorophenylthio)Benzoic Acid)
• 105442-23-7(3-cl-4-ch3s-c6h3-cooch3)